REG - Indivior PLC - Settlement with Dr. Reddy’s Laboratories

IndiviorAnnouncement

24/06/2022 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220624:nRSX1434Qa&default-theme=true

RNS Number : 1434Q  Indivior PLC  24 June 2022

 

 

Indivior Reaches Settlement with Dr. Reddy's Laboratories in Patent
Infringement Case

 

Slough, UK and Richmond, VA, June 24, 2022 - Indivior PLC, (LON: INDV)
announced that together with Aquestive Therapeutics, Inc. it entered into a
settlement agreement with Dr. Reddy's Laboratories Ltd. (DRL) and its
subsidiaries resolving patent litigation relating to DRL's generic
buprenorphine and naloxone sublingual film, a therapeutic equivalent generic
version of SUBOXONE® (buprenorphine and naloxone) sublingual film.  The
confidential settlement resolves all claims between the parties and the amount
paid by Indivior to DRL pursuant to the settlement is consistent with its
previously disclosed reserve amount.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world
will have access to evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from
a global human crisis to a recognized and treated chronic disease. Building on
its global portfolio of OUD treatments, Indivior has a pipeline of product
candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 900
individuals globally and its portfolio of products is available in over 40
countries worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=05%7C01%7Cjason.thompson%40Indivior.com%7C229aeec7b17246ed833208da55c46abe%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637916599362456007%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=u6JGYoyD%2BwG914fpSswN7wO0FA4meYgsYi4pnW78lRs%3D&reserved=0)
to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=05%7C01%7Cjason.thompson%40Indivior.com%7C229aeec7b17246ed833208da55c46abe%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C637916599362456007%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=3Frt76TdxC5aWlfbbQay8LOUSNG93zeBJTQoyQOJYIc%3D&reserved=0)
.

 

For Further Information

 

 Jason Thompson  VP, Investor Relations                     +1 804 402 7123

                 Indivior PLC                               jason.thompson@indivior.com
 Tim Owens       Director, Investor Relations Indivior PLC  +1 804 263 3978

                                                            timothy.owens@indivior.com

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBKQBQKBKDNAB